Related references
Note: Only part of the references are listed.The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
Nicholas G. Wysham et al.
CHEST (2013)
Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
Rowan Wathes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
Roger A. Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Foxp3+regulatory T cells, immune stimulation and host defence against infection
Jared H. Rowe et al.
IMMUNOLOGY (2012)
Ruxolitinib for myelofibrosis therapy: current context, pros and cons
A. Pardanani
LEUKEMIA (2012)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
Autoimmunity and the risk of myeloproliferative neoplasms
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?
Giovanni Barosi et al.
LEUKEMIA RESEARCH (2010)
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Kajsa Wing et al.
NATURE IMMUNOLOGY (2010)
Advances in Understanding and Management of Myeloproliferative Neoplasms
Alessandro M. Vannucchi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Interleukin-2 receptor downstream events in regulatory T cells - Implications for the choice of immunosuppressive drug therapy
Robert Zeiser et al.
CELL CYCLE (2008)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Share Paper
